Second-generation chimeric antigen receptors (CARs) retarget and reprogramme T cells to
augment their antitumour efficacy. The combined activating and co-stimulatory domains …

Twenty-five years ago, we reported that agonist anti-CD137 monoclonal antibodies
eradicated transplanted mouse tumors because of enhanced CD8+ T-cell antitumor …

Engineered T cells are effective therapies against a range of malignancies, but current
approaches rely on autologous T cells, which are difficult and expensive to manufacture …

Immunotherapy is a rapidly expanding field of oncology aimed at targeting, not the tumor
itself, but the immune system combating the cancerous lesion. Of the many approaches …

Costimulation of T cell responses with monoclonal antibody agonists (mAb-AG) targeting 4-
1BB showed robust anti-tumor activity in preclinical models, but their clinical development …

Trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2
(HER2; also known as HER-2/neu), is indicated for the treatment of women with either early …

Exosomes are a type of extracellular vesicle (EV) with diameters of 30–150 nm secreted by
most of the cells into the extracellular spaces and can alter the microenvironment through …

Natural killer (NK) cells are innate effector lymphocytes that control the growth of major
histocompatibility complex class I negative tumors. We show here that γδ T lymphocytes …

Treatment with cetuximab, an EGFR-targeting IgG1 mAb, results in beneficial, yet limited,
clinical improvement for patients with head and neck (HN) cancer as well as colorectal …

Antibody-dependent cell-mediated cytotoxicity (ADCC), which is largely mediated by natural
killer (NK) cells, is thought to play an important role in the efficacy of rituximab, an anti-CD20 …